Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1988 1
1989 1
1991 1
1997 2
1999 3
2001 4
2002 1
2004 3
2005 3
2006 2
2007 3
2008 3
2009 1
2010 4
2011 2
2012 1
2013 5
2014 6
2015 4
2016 4
2017 4
2018 3
2019 2
2020 3
2021 4
2022 4
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
Next Generation Therapeutics for the Treatment of Myelofibrosis.
Tremblay D, Mascarenhas J. Tremblay D, et al. Cells. 2021 Apr 27;10(5):1034. doi: 10.3390/cells10051034. Cells. 2021. PMID: 33925695 Free PMC article. Review.
Myelofibrosis is a myeloproliferative neoplasm characterized by splenomegaly, constitutional symptoms, bone marrow fibrosis, and a propensity towards transformation to acute leukemia. ...We also provide commentary on the future of therapeutic developme …
Myelofibrosis is a myeloproliferative neoplasm characterized by splenomegaly, constitutional symptoms, bone marrow fibrosis …
Management of myelofibrosis after ruxolitinib failure.
Harrison CN, Schaap N, Mesa RA. Harrison CN, et al. Ann Hematol. 2020 Jun;99(6):1177-1191. doi: 10.1007/s00277-020-04002-9. Epub 2020 Mar 20. Ann Hematol. 2020. PMID: 32198525 Free PMC article. Review.
Myelofibrosis is a BCR-ABL1-negative myeloproliferative neoplasm characterized by anemia, progressive splenomegaly, extramedullary hematopoiesis, bone marrow fibrosis, constitutional symptoms, leukemic progression, and shortened survival. Constitutive activat …
Myelofibrosis is a BCR-ABL1-negative myeloproliferative neoplasm characterized by anemia, progressive splenomegaly, extramedullary hematopoi …
Anemia in myelofibrosis: Current and emerging treatment options.
Passamonti F, Harrison CN, Mesa RA, Kiladjian JJ, Vannucchi AM, Verstovsek S. Passamonti F, et al. Crit Rev Oncol Hematol. 2022 Dec;180:103862. doi: 10.1016/j.critrevonc.2022.103862. Epub 2022 Nov 1. Crit Rev Oncol Hematol. 2022. PMID: 36332787 Free article. Review.
Myelofibrosis (MF) is a clonal hematologic malignancy with progressive bone marrow fibrosis. Clinical manifestations of MF include splenomegaly, constitutional symptoms, and anemia, whose pathogenesis is multifactorial and largely due to ineffective erythropo …
Myelofibrosis (MF) is a clonal hematologic malignancy with progressive bone marrow fibrosis. Clinical manifestations of …
Management of Myelofibrosis-Related Cytopenias.
Bose P, Verstovsek S. Bose P, et al. Curr Hematol Malig Rep. 2018 Jun;13(3):164-172. doi: 10.1007/s11899-018-0447-9. Curr Hematol Malig Rep. 2018. PMID: 29796726 Review.
Management of cytopenias in myelofibrosis can be very challenging because current therapeutic interventions are only of modest efficacy and ruxolitinib, the only approved drug for myelofibrosis, is myelosuppressive. ...Finally, several preclinical leads with translational …
Management of cytopenias in myelofibrosis can be very challenging because current therapeutic interventions are only of modest effica …
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety.
Verstovsek S, Mesa RA, Livingston RA, Hu W, Mascarenhas J. Verstovsek S, et al. J Hematol Oncol. 2023 Jul 27;16(1):82. doi: 10.1186/s13045-023-01471-z. J Hematol Oncol. 2023. PMID: 37501130 Free PMC article. Review.
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, anemia, extramedullary hematopoiesis, and splenomegaly. ...Over a decade later, ruxolitinib continues to be the standard of care in higher-risk MF, and d …
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, anemia, extramedulla …
Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A. Tefferi A. Am J Hematol. 2016 Dec;91(12):1262-1271. doi: 10.1002/ajh.24592. Am J Hematol. 2016. PMID: 27870387 Free article. Review.
Disease overview: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR or MPL mutation, abnormal cytokine expression, bone marrow fib …
Disease overview: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloprolifer …
Treatment of Myelofibrosis: A Moving Target.
Cerquozzi S, Farhadfar N, Tefferi A. Cerquozzi S, et al. Cancer J. 2016 Jan-Feb;22(1):51-61. doi: 10.1097/PPO.0000000000000169. Cancer J. 2016. PMID: 26841017 Review.
Myelofibrosis is characterized by stem cell-derived clonal myeloproliferation, abnormal cytokine expression, bone marrow fibrosis, anemia, splenomegaly, extramedullary hematopoiesis, constitutional symptoms, cachexia, leukemic progression, and shortened survi …
Myelofibrosis is characterized by stem cell-derived clonal myeloproliferation, abnormal cytokine expression, bone marrow fi …
Definition and management of ruxolitinib treatment failure in myelofibrosis.
Pardanani A, Tefferi A. Pardanani A, et al. Blood Cancer J. 2014 Dec 12;4(12):e268. doi: 10.1038/bcj.2014.84. Blood Cancer J. 2014. PMID: 25501025 Free PMC article. Review.
Accordingly, while ruxolitinib and other JAK inhibitors are effective in controlling splenomegaly and alleviating constitutional symptoms, their benefit in terms of reversing bone marrow fibrosis or inducing complete or partial remissions appears to be limite …
Accordingly, while ruxolitinib and other JAK inhibitors are effective in controlling splenomegaly and alleviating constitutional symptoms, t …
Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A. Tefferi A. Am J Hematol. 2013 Feb;88(2):141-50. doi: 10.1002/ajh.23384. Am J Hematol. 2013. PMID: 23349007 Free article. Review.
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by stem cell-derived clonal myeloproliferation, abnormal cytokine expression, bone marrow fibrosis, anemia, splenomegaly, extramedullary hematopoiesis (EMH), constitu …
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by stem cell-derived clonal myeloproliferation, …
Management of myelofibrosis: JAK inhibition and beyond.
Stahl M, Zeidan AM. Stahl M, et al. Expert Rev Hematol. 2017 May;10(5):459-477. doi: 10.1080/17474086.2017.1317590. Epub 2017 Apr 26. Expert Rev Hematol. 2017. PMID: 28395559 Review.
Myelofibrosis (MF) is characterized by bone marrow fibrosis with subsequent extramedullary hematopoiesis and abnormal cytokine expression leading to splenomegaly, constitutional symptoms and cytopenias. ...Expert commentary: Despite significant reduction of s …
Myelofibrosis (MF) is characterized by bone marrow fibrosis with subsequent extramedullary hematopoiesis and abnormal c …
71 results